Inderjit Singh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7666488/publications.pdf Version: 2024-02-01

		22548	46524
205	10,915	61	93
papers	citations	h-index	g-index
213	213	213	11337
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Neuroprotective effects of Alda-1 mitigate spinal cord injury in mice: involvement of Alda-1-induced ALDH2 activation-mediated suppression of reactive aldehyde mechanisms. Neural Regeneration Research, 2022, 17, 185.	1.6	7
2	Asymmetric dimethylarginine-induced oxidative damage leads to cerebrovascular dysfunction. Neural Regeneration Research, 2021, 16, 1793.	1.6	1
3	NAC and Vitamin D Restore CNS Glutathione in Endotoxin-Sensitized Neonatal Hypoxic-Ischemic Rats. Antioxidants, 2021, 10, 489.	2.2	7
4	Detoxification of Reactive Aldehydes by Alda-1 Treatment Ameliorates Experimental Autoimmune Encephalomyelitis in Mice. Neuroscience, 2021, 458, 31-42.	1.1	8
5	Hypoxiaâ€inducible factorâ€1 drives divergent immunomodulatory functions in the pathogenesis of autoimmune diseases. Immunology, 2021, 164, 31-42.	2.0	20
6	GSNOR and ALDH2 alleviate traumatic spinal cord injury. Brain Research, 2021, 1758, 147335.	1.1	3
7	Vascular and immunopathological role of Asymmetric Dimethylarginine (ADMA) in Experimental Autoimmune Encephalomyelitis. Immunology, 2021, 164, 602-616.	2.0	4
8	Regulation of B cell functions by S-nitrosoglutathione in the EAE model. Redox Biology, 2021, 45, 102053.	3.9	11
9	Peroxisomal footprint in the pathogenesis of nonalcoholic steatohepatitis. Annals of Hepatology, 2020, 19, 466-471.	0.6	9
10	Targeting GSNOR for functional recovery in a middle-aged mouse model of stroke. Brain Research, 2020, 1741, 146879.	1,1	5
11	Investigation of S-Nitrosoglutathione in stroke: A systematic review and meta-analysis of literature in pre-clinical and clinical research. Experimental Neurology, 2020, 328, 113262.	2.0	6
12	Asymmetric dimethylarginine exacerbates cognitive dysfunction associated with cerebrovascular pathology. FASEB Journal, 2020, 34, 6808-6823.	0.2	11
13	S-Nitrosoglutathione Mimics the Beneficial Activity of Endothelial Nitric Oxide Synthase-Derived Nitric Oxide in a Mouse Model of Stroke. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104470.	0.7	10
14	Regulation of endothelial barrier integrity by redox-dependent nitric oxide signaling: Implication in traumatic and inflammatory brain injuries. Nitric Oxide - Biology and Chemistry, 2019, 83, 51-64.	1.2	12
15	Therapeutic exploitation of the S-nitrosoglutathione/S-nitrosylation mechanism for the treatment of contusion spinal cord injury. Neural Regeneration Research, 2019, 14, 973.	1.6	5
16	Abstract TP105: Investigation of S-nitrosoglutathione in Stroke: A Systematic Review of Literature in Pre-Clinical and Clinical Research. Stroke, 2019, 50, .	1.0	0
17	Combination therapy of lovastatin and <scp>AMP</scp> â€activated protein kinase activator improves mitochondrial and peroxisomal functions and clinical disease in experimental autoimmune encephalomyelitis model. Immunology, 2018, 154, 434-451.	2.0	20
18	S-nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis. Free Radical Biology and Medicine, 2018, 121, 57-68.	1.3	17

#	Article	IF	CITATIONS
19	GSNO promotes functional recovery in experimental TBI by stabilizing HIF-1α. Behavioural Brain Research, 2018, 340, 63-70.	1.2	23
20	Pathology of nNOS-Expressing GABAergic Neurons in Mouse Model of Alzheimer's Disease. Neuroscience, 2018, 384, 41-53.	1.1	21
21	Protective effect of S-nitrosoglutathione administration against hyperglycemia induced disruption of blood brain barrier is mediated by modulation of tight junction proteins and cell adhesion molecules. Neurochemistry International, 2018, 118, 205-216.	1.9	12
22	Regulation of IL-10 and IL-17 mediated experimental autoimmune encephalomyelitis by S-nitrosoglutathione. Immunobiology, 2018, 223, 549-554.	0.8	10
23	Combined treatment with GSNO and CAPE accelerates functional recovery via additive antioxidant activities in a mouse model of TBI. Journal of Neuroscience Research, 2018, 96, 1900-1913.	1.3	10
24	Amelioration of spinal cord injury in rats by blocking peroxynitrite/calpain activity. BMC Neuroscience, 2018, 19, 50.	0.8	10
25	S-Nitrosylation in Regulation of Inflammation and Cell Damage. Current Drug Targets, 2018, 19, 1831-1838.	1.0	9
26	MicroRNA Profiling Identifies miR-196a as Differentially Expressed in Childhood Adrenoleukodystrophy and Adult Adrenomyeloneuropathy. Molecular Neurobiology, 2017, 54, 1392-1403.	1.9	10
27	Regulation of STAT3 and NF-κB activations by S-nitrosylation in multiple myeloma. Free Radical Biology and Medicine, 2017, 106, 245-253.	1.3	18
28	Vitamin D improves functional outcomes in neonatal hypoxic ischemic male rats treated with N -acetylcysteine and hypothermia. Neuropharmacology, 2017, 123, 186-200.	2.0	20
29	Hypoxia inducible factor-1 alpha stabilization for regenerative therapy in traumatic brain injury. Neural Regeneration Research, 2017, 12, 696.	1.6	29
30	Sex-specific effects of N-acetylcysteine in neonatal rats treated with hypothermia after severe hypoxia-ischemia. Neuroscience Research, 2016, 108, 24-33.	1.0	34
31	S-Nitrosoglutathione ameliorates acute renal dysfunction in a rat model of lipopolysaccharide-induced sepsis. Journal of Pharmacy and Pharmacology, 2016, 68, 1310-1319.	1.2	19
32	Cardiovascular Disease, Statins, and HIV. Journal of Infectious Diseases, 2016, 214, S83-S92.	1.9	25
33	Biochemical, cell biological, pathological, and therapeutic aspects of <scp>K</scp> rabbe's disease. Journal of Neuroscience Research, 2016, 94, 990-1006.	1.3	42
34	Targeting the nNOS/peroxynitrite/calpain system to confer neuroprotection and aid functional recovery in a mouse model of TBI. Brain Research, 2016, 1630, 159-170.	1.1	36
35	Inhibition of the AMPK/nNOS pathway for neuroprotection in stroke. Neural Regeneration Research, 2016, 11, 398.	1.6	3
36	STAT3 Regulation By S-Nitrosylation: Implication In Cancer. Redox Biology, 2015, 5, 416-417.	3.9	11

#	Article	IF	CITATIONS
37	S-Nitrosoglutathione protects the spinal bladder: Novel therapeutic approach to post-spinal cord injury bladder remodeling. Neurourology and Urodynamics, 2015, 34, 519-526.	0.8	14
38	Effect of vitamin D3 intake on the onset of disease in a murine model of human Krabbe disease. Journal of Neuroscience Research, 2015, 93, 28-42.	1.3	14
39	Promoting endothelial function by S-nitrosoglutathione through the HIF-1α/VECF pathway stimulates neurorepair and functional recovery following experimental stroke in rats. Drug Design, Development and Therapy, 2015, 9, 2233.	2.0	45
40	AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis. PLoS ONE, 2015, 10, e0141781.	1.1	8
41	<scp>ABCD</scp> 1 deletionâ€induced mitochondrial dysfunction is corrected by <scp>SAHA</scp> : implication for adrenoleukodystrophy. Journal of Neurochemistry, 2015, 133, 380-396.	2.1	33
42	Blocking a vicious cycle nNOS/peroxynitrite/AMPK by S-nitrosoglutathione: implication for stroke therapy. BMC Neuroscience, 2015, 16, 42.	0.8	32
43	Role of S-nitrosoglutathione mediated mechanisms in tau hyper-phosphorylation. Biochemical and Biophysical Research Communications, 2015, 458, 214-219.	1.0	14
44	S-nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma. Redox Biology, 2015, 6, 41-50.	3.9	28
45	Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in rats. Journal of Neuroinflammation, 2015, 12, 94.	3.1	22
46	S-nitrosoglutathione reduces tau hyper-phosphorylation and provides neuroprotection in rat model of chronic cerebral hypoperfusion. Brain Research, 2015, 1624, 359-369.	1.1	10
47	<i>S</i> â€nitrosoglutathione prevents blood–brain barrier disruption associated with increased matrix metalloproteinaseâ€9 activity in experimental diabetes. Journal of Neurochemistry, 2015, 132, 595-608.	2.1	29
48	Functional Characterization of IPSC-Derived Brain Cells as a Model for X-Linked Adrenoleukodystrophy. PLoS ONE, 2015, 10, e0143238.	1.1	21
49	An NO/CSNO-based Neuroregeneration Strategy for Stroke Therapy. Journal of Neurology and Neuroscience, 2015, 6, .	0.4	4
50	STAT3 Regulation by S-Nitrosylation: Implication for Inflammatory Disease. Antioxidants and Redox Signaling, 2014, 20, 2514-2527.	2.5	80
51	PPARα Activation Induces <i>N</i> ^ε ‣ysâ€Acetylation of Rat Liver Peroxisomal Multifunctional Enzyme Type 1. Lipids, 2014, 49, 119-131.	0.7	1
52	AMP-Activated Protein Kinase Signaling Protects Oligodendrocytes that Restore Central Nervous System Functions in an Experimental Autoimmune Encephalomyelitis Model. American Journal of Pathology, 2013, 183, 526-541.	1.9	50
53	Simvastatin Ameliorates Cauda Equina Compression Injury in a Rat Model of Lumbar Spinal Stenosis. Journal of NeuroImmune Pharmacology, 2013, 8, 274-286.	2.1	18
54	S-Nitrosoglutathione Induces Ciliary Neurotrophic Factor Expression in Astrocytes, Which Has Implications to Protect the Central Nervous System under Pathological Conditions. Journal of Biological Chemistry, 2013, 288, 3831-3843.	1.6	31

#	Article	IF	CITATIONS
55	Role of endogenous psychosine accumulation in oligodendrocyte differentiation and survival: Implication for Krabbe disease. Brain Research, 2013, 1508, 44-52.	1.1	37
56	Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 747-758.	1.2	15
57	Modulation of Rhoâ€Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPARâ€Î±â€dependent mechanism. Glia, 2013, 61, 1500-1517.	2.5	36
58	Protective Role of S-Nitrosoglutathione (GSNO) Against Cognitive Impairment in Rat Model of Chronic Cerebral Hypoperfusion. Journal of Alzheimer's Disease, 2013, 34, 621-635.	1.2	52
59	Histone Deacetylase Inhibitor Upregulates Peroxisomal Fatty Acid Oxidation and Inhibits Apoptotic Cell Death in Abcd1-Deficient Glial Cells. PLoS ONE, 2013, 8, e70712.	1.1	15
60	Combinatorial Effect of Metformin and Lovastatin Impedes T-cell Autoimmunity and Neurodegeneration in Experimental Autoimmune Encephalomyelitis. Journal of Clinical & Cellular Immunology, 2013, 04, .	1.5	21
61	Stimulation of functional recovery via the mechanisms of neurorepair by S-nitrosoglutathione and motor exercise in a rat model of transient cerebral ischemia and reperfusion. Restorative Neurology and Neuroscience, 2012, 30, 383-396.	0.4	49
62	Interference with RhoA–ROCK Signaling Mechanism in Autoreactive CD4+ T Cells Enhances the Bioavailability of 1,25-Dihydroxyvitamin D3 in Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2012, 181, 993-1006.	1.9	20
63	The inhibitory effect of Sâ€nitrosoglutathione on blood–brain barrier disruption and peroxynitrite formation in a rat model of experimental stroke. Journal of Neurochemistry, 2012, 123, 86-97.	2.1	62
64	S-Nitrosoglutathione Administration Ameliorates Cauda Equina Compression Injury in Rats. Neuroscience and Medicine, 2012, 03, 294-305.	0.2	12
65	N-acetylcysteine attenuates the maternal and fetal proinflammatory response to intrauterine LPS injection in an animal model for preterm birth and brain injury. Journal of Maternal-Fetal and Neonatal Medicine, 2011, 24, 732-740.	0.7	33
66	Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis. Journal of Neurochemistry, 2011, 116, 508-521.	2.1	87
67	S-Nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats. Journal of Neuroinflammation, 2011, 8, 78.	3.1	89
68	Preclinical use of longitudinal MRI for screening the efficacy of sâ€nitrosoglutathione in treating spinal cord injury. Journal of Magnetic Resonance Imaging, 2011, 33, 1301-1311.	1.9	25
69	HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes. Journal of Lipid Research, 2011, 52, 2056-2069.	2.0	29
70	Pathomechanisms Underlying Xâ€Adrenoleukodystrophy: A Threeâ€Hit Hypothesis. Brain Pathology, 2010, 20, 838-844.	2.1	116
71	S-nitrosoglutathione a Physiologic Nitric Oxide Carrier Attenuates Experimental Autoimmune Encephalomyelitis. Journal of NeuroImmune Pharmacology, 2010, 5, 240-251.	2.1	49
72	Activation of PPARâ€Î³ and PTEN cascade participates in lovastatinâ€mediated accelerated differentiation of oligodendrocyte progenitor cells. Glia, 2010, 58, 1669-1685.	2.5	39

#	Article	IF	CITATIONS
73	Simvastatin protects bladder and renal functions following spinal cord injury in rats. Journal of Inflammation, 2010, 7, 17.	1.5	23
74	Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy. Journal of Lipid Research, 2010, 51, 1685-1695.	2.0	36
75	Factors that affect postnatal bone growth retardation in the twitcher murine model of Krabbe disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 601-608.	1.8	12
76	Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis. Biochemical and Biophysical Research Communications, 2010, 399, 487-491.	1.0	71
77	Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis. Journal of Immunology, 2009, 182, 8005-8014.	0.4	304
78	Peroxisomal Dysfunction in Inflammatory Childhood White Matter Disorders: An Unexpected Contributor to Neuropathology. Journal of Child Neurology, 2009, 24, 1147-1157.	0.7	29
79	Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy. Journal of Lipid Research, 2009, 50, 135-147.	2.0	60
80	Neuroprotective Interventions: Is It Too Late?. Journal of Child Neurology, 2009, 24, 1212-1219.	0.7	16
81	Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia, 2009, 57, 182-193.	2.5	52
82	Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. Biochemical and Biophysical Research Communications, 2009, 386, 16-20.	1.0	64
83	Reduction of lipoxidative load by secretory phospholipase A2 inhibition protects against neurovascular injury following experimental stroke in rat. Journal of Neuroinflammation, 2009, 6, 21.	3.1	40
84	Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact. Journal of Neuroinflammation, 2009, 6, 32.	3.1	127
85	15-deoxy-delta12,14-prostaglandin J2 attenuates endothelial-monocyte interaction: implication for inflammatory diseases. Journal of Inflammation, 2008, 5, 14.	1.5	20
86	Modulation of peroxisome proliferator-activated receptor-α activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipopolysaccharide stimulated mixed glial cultures. Journal of Neurochemistry, 2008, 105, 956-970.	2.1	35
87	The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe Disease. Journal of Neurochemistry, 2008, 105, 1820-1833.	2.1	68
88	Lovastatin inhibits amyloid precursor protein (APP) βâ€cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts. Journal of Neurochemistry, 2008, 105, 1536-1549.	2.1	37
89	Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. Journal of Neurochemistry, 2008, 106, 1766-1779.	2.1	69
90	Oxidative Imbalance in Nonstimulated X-Adrenoleukodystrophy-Derived Lymphoblasts. Developmental Neuroscience, 2008, 30, 410-418.	1.0	40

#	Article	IF	CITATIONS
91	Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death. Neuroscience Letters, 2008, 440, 260-264.	1.0	92
92	Psychosine-induced alterations in peroxisomes of twitcher mouse liver. Archives of Biochemistry and Biophysics, 2008, 477, 211-218.	1.4	15
93	Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matter injury: Attenuation by N-acetyl cysteine. Experimental Neurology, 2008, 210, 560-576.	2.0	81
94	Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Experimental Neurology, 2008, 214, 168-180.	2.0	33
95	Inhibition of Rho Family Functions by Lovastatin Promotes Myelin Repair in Ameliorating Experimental Autoimmune Encephalomyelitis. Molecular Pharmacology, 2008, 73, 1381-1393.	1.0	64
96	Attenuation of Lipopolysaccharide-Induced Inflammatory Response and Phospholipids Metabolism at the Feto-Maternal Interface by N-Acetyl Cysteine. Pediatric Research, 2008, 64, 334-339.	1.1	35
97	Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. Future Neurology, 2008, 3, 153-167.	0.9	25
98	Metformin, a diabetic drug attenuated autoimmune inflammatory disease of CNS in animal models of multiple sclerosis. FASEB Journal, 2008, 22, 1074.7.	0.2	0
99	Lysine acetylation: a new protein modification in PPARâ€alpha agonist induced peroxisomes. FASEB Journal, 2008, 22, 1026.10.	0.2	0
100	GSNO attenuates EAE disease byS-nitrosylation-mediated modulation of endothelial-monocyte interactions. Glia, 2007, 55, 65-77.	2.5	83
101	Caffeic acid phenethyl ester reduces neurovascular inflammation and protects rat brain following transient focal cerebral ischemia. Journal of Neurochemistry, 2007, 102, 365-377.	2.1	97
102	Lactosylceramide: a lipid second messenger in neuroinflammatory disease. Journal of Neurochemistry, 2007, 103, 180-191.	2.1	47
103	Hepatic toxicity in twitcher mice: effect on peroxisomes. FASEB Journal, 2007, 21, .	0.2	0
104	Tumor Necrosis Factorâ€[Alpha] regulates lactosylceramide synthesis via activation of Protein Kinase C: A novel function of Giâ€linked sphingosineâ€1â€phosphate receptor. FASEB Journal, 2007, 21, A604.	0.2	0
105	Immunomodulatory Effect of Combination Therapy with Lovastatin and 5-Aminoimidazole-4-Carboxamide-1-β-d-Ribofuranoside Alleviates Neurodegeneration in Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2006, 169, 1012-1025.	1.9	41
106	Inhibition of NF-kappaB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia. Journal of Neuroinflammation, 2006, 3, 12.	3.1	82
107	Molecular organization of peroxisomal enzymes: Protein–protein interactions in the membrane and in the matrix. Archives of Biochemistry and Biophysics, 2006, 451, 128-140.	1.4	20
108	Dysfunction of peroxisomes in twitcher mice brain: A possible mechanism of psychosine-induced disease. Biochemical and Biophysical Research Communications, 2006, 343, 229-238.	1.0	38

#	Article	IF	CITATIONS
109	Pharmacological strategies for the regulation of inducible nitric oxide synthase: Neurodegenerative versus neuroprotective mechanisms. Neurochemistry International, 2006, 49, 170-182.	1.9	169
110	Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke. Nitric Oxide - Biology and Chemistry, 2006, 15, 114-124.	1.2	95
111	Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. Journal of Neurochemistry, 2006, 101, 182-200.	2.1	82
112	T-bet is essential for the progression of experimental autoimmune encephalomyelitis. Immunology, 2006, 118, 384-391.	2.0	72
113	Sphingolipid signaling and redox regulation. Free Radical Biology and Medicine, 2006, 40, 1875-1888.	1.3	121
114	Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. Journal of Neuroimmunology, 2006, 178, 130-139.	1.1	40
115	5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial–monocyte interaction. Journal of Neuroscience Research, 2006, 84, 614-625.	1.3	67
116	Combination of Systemic Hypothermia and N-acetylcysteine Attenuates Hypoxic-Ischemic Brain Injury in Neonatal Rats. Pediatric Research, 2006, 59, 684-689.	1.1	112
117	IL-4-Induced Peroxisome Proliferator-Activated Receptor Î ³ Activation Inhibits NF-Î ^e B <i>Trans</i> Activation in Central Nervous System (CNS) Glial Cells and Protects Oligodendrocyte Progenitors under Neuroinflammatory Disease Conditions: Implication for CNS-Demyelinating Diseases. Journal of Immunology, 2006, 176, 4385-4398.	0.4	70
118	Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappaB pathway by lovastatin limits endothelial-monocyte cell interaction. Journal of Neurochemistry, 2005, 94, 204-214.	2.1	50
119	S-Nitrosoglutathione Reduces Inflammation and Protects Brain against Focal Cerebral Ischemia in a Rat Model of Experimental Stroke. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 177-192.	2.4	150
120	Involvement of phospholipase A2 and lipoxygenase in lipopolysaccharide-induced inducible nitric oxide synthase expression in glial cells. Glia, 2005, 51, 13-21.	2.5	26
121	Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. Journal of Neuroscience Research, 2005, 79, 340-350.	1.3	116
122	Peroxisomal participation in psychosine-mediated toxicity: Implications for Krabbe's disease. Journal of Neuroscience Research, 2005, 80, 845-854.	1.3	54
123	HMC oA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB Journal, 2005, 19, 1407-1421.	0.2	100
124	5-Aminoimidazole-4-Carboxamide Ribonucleoside: A Novel Immunomodulator with Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2005, 175, 566-574.	0.4	128
125	A Novel Role of Lactosylceramide in the Regulation of Tumor Necrosis Factor α-mediated Proliferation of Rat Primary Astrocytes. Journal of Biological Chemistry, 2005, 280, 13742-13751.	1.6	36
126	N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats. Journal of Autoimmune Diseases, 2005, 2, 4.	1.0	44

#	Article	IF	CITATIONS
127	Adenosine kinase inhibitor attenuates the expression of inducible nitric oxide synthase in glial cells. Neuropharmacology, 2005, 48, 151-160.	2.0	12
128	5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuates the expression of LPS- and Abeta peptide-induced inflammatory mediators in astroglia. Journal of Neuroinflammation, 2005, 2, 21.	3.1	39
129	A Novel Role of Lactosylceramide in the Regulation of Lipopolysaccharide/Interferon-Â-Mediated Inducible Nitric Oxide Synthase Gene Expression: Implications for Neuroinflammatory Diseases. Journal of Neuroscience, 2004, 24, 5942-5954.	1.7	68
130	The 15-Deoxy-δ12,14-Prostaglandin J2 Inhibits the Inflammatory Response in Primary Rat Astrocytes via Down-Regulating Multiple Steps in Phosphatidylinositol 3-Kinase-Akt-NF-κB-p300 Pathway Independent of Peroxisome Proliferator-Activated Receptor γ. Journal of Immunology, 2004, 173, 5196-5208.	0.4	128
131	5-Aminoimidazole-4-Carboxamide-1-Â-4-Ribofuranoside Inhibits Proinflammatory Response in Glial Cells: A Possible Role of AMP-Activated Protein Kinase. Journal of Neuroscience, 2004, 24, 479-487.	1.7	260
132	Potential Targets of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor for Multiple Sclerosis Therapy. Journal of Immunology, 2004, 172, 1273-1286.	0.4	159
133	Inflammatory mediator and β-amyloid (25–35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radical Biology and Medicine, 2004, 37, 325-338.	1.3	116
134	Dual role of cAMP in iNOS expression in glial cells and macrophages is mediated by differential regulation of p38-MAPK/ATF-2 activation and iNOS stability. Free Radical Biology and Medicine, 2004, 37, 1834-1844.	1.3	38
135	Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Research, 2004, 1022, 1-11.	1.1	59
136	Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. Journal of Neuroscience Research, 2004, 76, 519-527.	1.3	218
137	Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. Journal of Neuroscience Research, 2004, 77, 63-81.	1.3	74
138	N-acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain. Journal of Neuroscience Research, 2004, 78, 347-361.	1.3	157
139	Inflammatory mediator and \$beta;-amyloid (25?35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radical Biology and Medicine, 2004, 37, 325-325.	1.3	2
140	Inhibition of peroxisomal functions due to oxidative imbalance induced by mistargeting of catalase to cytoplasm is restored by vitamin E treatment in skin fibroblasts from Zellweger syndrome-like patients. Molecular Genetics and Metabolism, 2004, 83, 297-305.	0.5	14
141	Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet, The, 2004, 363, 1607-1608.	6.3	456
142	Statins for multiple sclerosis. Lancet, The, 2004, 364, 412-413.	6.3	5
143	Attenuation of Ischemia-Reperfusion Injury in a Canine Model of Autologous Renal Transplantation. Transplantation, 2004, 78, 654-659.	0.5	34
144	Rho a negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKα. Free Radical Biology and Medicine, 2003, 35, 1037-1050.	1.3	48

#	Article	IF	CITATIONS
145	N-Acetyl cysteine protects against injury in a rat model of focal cerebral ischemia. Brain Research, 2003, 971, 1-8.	1.1	138
146	Molecular mechanism of psychosine-induced cell death in human oligodendrocyte cell line. Journal of Neurochemistry, 2003, 86, 1428-1440.	2.1	98
147	The role of neutral sphingomyelinase produced ceramide in lipopolysaccharide-mediated expression of inducible nitric oxide synthase. Journal of Neurochemistry, 2003, 88, 583-593.	2.1	48
148	Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD:. Neurobiology of Disease, 2003, 14, 425-439.	2.1	108
149	Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiology of Disease, 2003, 14, 425-425.	2.1	10
150	The Involvement of Glucose Metabolism in the Regulation of Inducible Nitric Oxide Synthase Gene Expression in Glial Cells: Possible Role of Glucose-6-Phosphate Dehydrogenase and CCAAT/Enhancing Binding Protein. Journal of Neuroscience, 2003, 23, 7470-7478.	1.7	39
151	Galactosylsphingosine (psychosine) â€induced expression of cytokineâ€mediated inducible nitric oxide synthases via APâ€1 and C/EBP: implications for Krabbe disease. FASEB Journal, 2002, 16, 661-672.	0.2	92
152	[31] Peroxisomal fatty acid oxidation and cellular redox. Methods in Enzymology, 2002, 352, 361-372.	0.4	11
153	Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neuroscience Letters, 2002, 333, 167-170.	1.0	72
154	Interleukin-10 and Interleukin-13 Inhibit Proinflammatory Cytokine-Induced Ceramide Production Through the Activation of Phosphatidylinositol 3-Kinase. Journal of Neurochemistry, 2002, 75, 576-582.	2.1	63
155	Induction of the Manganese Superoxide Dismutase Gene by Sphingomyelinase and Ceramide. Journal of Neurochemistry, 2002, 73, 513-520.	2.1	26
156	Combination therapy of N-acetylcysteine, sodium nitroprusside and phosphoramidon attenuates ischemia-reperfusion injury in rat kidney. Molecular and Cellular Biochemistry, 2002, 240, 9-17.	1.4	37
157	Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. Journal of Neuroscience Research, 2001, 66, 155-162.	1.3	144
158	Endotoxin induces structure-function alterations of rat liver peroxisomes: Kupffer cells released factors as possible modulators. Hepatology, 2000, 31, 446-455.	3.6	26
159	Characterization of fibroblast cytoplasmic proteins that bind to the 3' UTR of human catalase mRNA. Molecular and Cellular Biochemistry, 2000, 209, 9-15.	1.4	4
160	Isolation and biochemical characterization of peroxisomes from cultured rat glial cells. Neurochemical Research, 2000, 25, 197-203.	1.6	12
161	Identification of the pathway of \hat{l} ±-oxidation of cerebronic acid in peroxisomes. Lipids, 2000, 35, 1127-1133.	0.7	11
162	Inducible Nitric Oxide Synthase in the Central Nervous System of Patients with X-Adrenoleukodystrophy. Journal of Neuropathology and Experimental Neurology, 2000, 59, 1063-1069.	0.9	62

#	Article	IF	CITATIONS
163	Intraperoxisomal Localization of Very-Long-Chain Fatty Acyl-CoA Synthetase: Implication in X-Adrenoleukodystrophy. Experimental Cell Research, 2000, 254, 309-320.	1.2	28
164	Lovastatin Therapy for X-Linked Adrenoleukodystrophy: Clinical and Biochemical Observations on 12 Patients. Molecular Genetics and Metabolism, 2000, 69, 312-322.	0.5	66
165	Endotoxin-induced alterations of lipid and fatty acid compositions in rat liver peroxisomes. Journal of Endotoxin Research, 2000, 6, 41-50.	2.5	39
166	Effect of Nitric Oxide on Rhinovirus Replication and Virus-Induced Interleukin-8 Elaboration. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 1193-1198.	2.5	25
167	Manganese superoxide dismutase in rat liver peroxisomes: biochemical and immunochemical evidence. Molecular and Cellular Biochemistry, 1999, 197, 7-12.	1.4	19
168	Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neuroscience Letters, 1999, 269, 71-74.	1.0	161
169	N-Acetyl Cysteine Inhibits Induction of No Production By Endotoxin or Cytokine Stimulated Rat Peritoneal Macrophages, C6 Glial Cells and Astrocytes. Free Radical Biology and Medicine, 1998, 24, 39-48.	1.3	155
170	Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy. FEBS Letters, 1998, 426, 342-346.	1.3	81
171	Restoration of phytanic acid oxidation in Refsum disease fibroblasts from patients with mutations in the phytanoyl-CoA hydroxylase gene. FEBS Letters, 1998, 429, 119-122.	1.3	13
172	Cytokine-mediated Induction of Ceramide Production Is Redox-sensitive. Journal of Biological Chemistry, 1998, 273, 20354-20362.	1.6	187
173	Lovastatin for X-Linked Adrenoleukodystrophy. New England Journal of Medicine, 1998, 339, 702-703.	13.9	97
174	Sphingomyelinase and Ceramide Stimulate the Expression of Inducible Nitric-oxide Synthase in Rat Primary Astrocytes. Journal of Biological Chemistry, 1998, 273, 2591-2600.	1.6	155
175	Cytokineâ€Induced Accumulation of Very Longâ€Chain Fatty Acids in Rat C6 Glial Cells: Implication for Xâ€Adrenoleukodystrophy. Journal of Neurochemistry, 1998, 71, 78-87.	2.1	46
176	Localization of nervonic acid β-oxidation in human and rodent peroxisomes: impaired oxidation in Zellweger syndrome and X-linked adrenoleukodystrophy. Journal of Lipid Research, 1998, 39, 2161-2171.	2.0	37
177	Increasing cAMP Attenuates Induction of Inducible Nitric-oxide Synthase in Rat Primary Astrocytes. Journal of Biological Chemistry, 1997, 272, 7786-7791.	1.6	128
178	Cytochrome P-450 2E1 in Rat Liver Peroxisomes. Free Radical Biology and Medicine, 1997, 23, 963-971.	1.3	43
179	Biochemical Features of a Patient with Zellweger-like Syndrome with Normal PTS-1 and PTS-2 Peroxisomal Protein Import Systems: A New Peroxisomal Disease. Biochemical and Molecular Medicine, 1997, 61, 198-207.	1.5	8
180	Title is missing!. Molecular and Cellular Biochemistry, 1997, 176, 337-347.	1.4	27

#	Article	IF	CITATIONS
181	Biochemistry of peroxisomes in health and disease. , 1997, 167, 1-29.		130
182	Modulation of Endogenous Antioxidant Enzymes by Nitric Oxide in Rat C ₆ Glial Cells. Journal of Neurochemistry, 1997, 68, 1896-1903.	2.1	84
183	Targeted Disruption of the Peroxisomal Fatty Acyl-CoA Oxidase Gene: Generation of a Mouse Model of Pseudoneonatal Adrenoleukodystrophy. Annals of the New York Academy of Sciences, 1996, 804, 530-541.	1.8	23
184	Mammalian Peroxisomes: Metabolism of Oxygen and Reactive Oxygen Species. Annals of the New York Academy of Sciences, 1996, 804, 612-627.	1.8	65
185	Abnormality in Translational Regulation of Catalase Expression in Disorders of Peroxisomal Biogenesis. Journal of Neurochemistry, 1996, 67, 2373-2378.	2.1	9
186	Effect of Hypoxia-Reoxygenation on Peroxisomal Functions in Cultured Human Skin Fibroblasts from Control and Zellweger Syndrome Patients. Free Radical Research, 1995, 22, 39-46.	1.5	13
187	Ketoconazole and other imidazole derivatives are potent inhibitors of peroxisomal phytanic acid α-oxidation. FEBS Letters, 1995, 377, 213-216.	1.3	10
188	Impairment of peroxisomal ?-oxidation system by endotoxin treatment. Molecular and Cellular Biochemistry, 1994, 135, 187-193.	1.4	9
189	Expression of antioxidant enzymes in rat kidney during ischemia-reperfusion injury. Molecular and Cellular Biochemistry, 1993, 125, 97-104.	1.4	96
190	Peroxisomal participation in the cellular response to the oxidative stress of endotoxin. Molecular and Cellular Biochemistry, 1993, 126, 25-35.	1.4	42
191	Intraorganellar localization of CoASH-independent phytanic acid oxidation in human liver peroxisomes. FEBS Letters, 1993, 333, 154-158.	1.3	18
192	Identification of phytanoyl-CoA ligase as a distinct acyl-CoA ligase in peroxisomes from cultured human skin fibroblasts. FEBS Letters, 1993, 322, 101-104.	1.3	26
193	Purification of peroxisomes and subcellular distribution of enzyme activities for activation and oxidation of very-long-chain fatty acids in rat brain. Lipids and Lipid Metabolism, 1993, 1170, 44-52.	2.6	20
194	Phytanic acid α-oxidation in human cultured skin fibroblasts. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1992, 1180, 221-224.	1.8	28
195	Ischemia-reperfusion injury: Biochemical alterations in peroxisomes of rat kidney. Archives of Biochemistry and Biophysics, 1992, 295, 90-100.	1.4	61
196	Postnatal Development and Isolation of Peroxisomes from Brain. Journal of Neurochemistry, 1991, 56, 1343-1353.	2.1	61
197	Effect of ciprofibrate on the activation and oxidation of very long chain fatty acids. Molecular and Cellular Biochemistry, 1991, 100, 159-67.	1.4	20
198	Lignoceroyl-CoASH ligase: enzyme defect in fatty acid β-oxidation system in X-linked childhood adrenoleukodystrophy. FEBS Letters, 1986, 196, 247-250.	1.3	153

#	Article	IF	CITATIONS
199	Peroxisomal oxidation of lignoceric acid in rat brain. Neurochemical Research, 1986, 11, 281-289.	1.6	15
200	Lignoceroyl-CoA ligase activity in rat brain microsomal fraction: Topographical localization and effect of detergents and α-cyclodextrin. Archives of Biochemistry and Biophysics, 1985, 236, 418-426.	1.4	47
201	Adrenoleukodystrophy: Impaired Oxidation of Very Long Chain Fatty Acids in White Blood Cells, Cultured Skin Fibroblasts, and Amniocytes. Pediatric Research, 1984, 18, 286-290.	1.1	219
202	Adrenoleukodystrophy: Survey of 303 cases: Biochemistry, diagnosis, and therapy. Annals of Neurology, 1984, 16, 628-641.	2.8	258
203	Brain-specific ceramide synthesis activity: change during brain maturation and in jimpy mouse brain. Brain Research, 1982, 232, 500-505.	1.1	7
204	Adrenoleukodystrophy: Impaired oxidation of long chain fatty acids in cultured skin fibroblasts and adrenal cortex. Biochemical and Biophysical Research Communications, 1981, 102, 1223-1229.	1.0	128
205	Fatty acid ?-hydroxylation and its relation to myelination. Molecular and Cellular Biochemistry, 1979, 28, 93-105.	1.4	44